Long-term results after primary successful FK 506 treatment of steroid- and OKT3-resistant rejection in renal transplant recipients.
Kliem
V
V
Abteilung Nephrologie Zentrum Innere Medizin, Medizinische Hochschule Hannover, Germany.
Schaumann
D
D
Ehlerding
G
G
Eberhard
O K
OK
Lufft
V
V
Schlitt
H J
HJ
Pichlmayr
R
R
Koch
K M
KM
Brunkhorst
R
R
D000328:Adult; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D016559:Tacrolimus / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016559:Tacrolimus